The U.S. Supreme Court's rejection of natural DNA patent protection could hurt biotech companies, but specialists said it left enough safeguards for the industry to keep innovating.The court ruled that Myriad Genetics, which sells expensive tests for the genetic markers for cancer, could not claim patents on the DNA it identified in the 1990s to develop the tests. Read the full story